A Study of BR111 in Patients With Advanced Malignancies
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignancies
- Interventions
- Drug: BR111 for Injection
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT06937957
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Cancer, Shang Hai, Pudong New Area, China
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Phase 2
Not yet recruiting
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT06642909
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Malignancies
- Interventions
- Drug: BR115 for injection
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06388902
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BRY805 in Participants With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: BRY805 injection
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06289894
- Locations
- 🇨🇳
Shandong Tumor hospital, Jinan, Shandong, China
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06126718
A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignancies
- Interventions
- Drug: BRY812 for injection
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT06038058
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase I Study of BR108 in Hematological Malignancies
Phase 1
Recruiting
- Conditions
- Hematologic Malignancy
- Interventions
- Drug: BR108 injection
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06018506
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06001580
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China
Phase I/II Clinical Study of 1A46 Drug Substance
Phase 1
Terminated
- Conditions
- Advanced Malignancies
- Interventions
- Drug: 1A46 Drug Substance
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT05987605
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Phase I Clinical Study of BR105 Injection
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignancies
- Interventions
- Drug: BR105 injection
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT05351697
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath